- Home
- CRVS vs RPAY Comparison
CRVS vs RPAY Comparison
Compare CRVS & RPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- RPAY
- Stock Information
- Founded
- CRVS 2014
- RPAY 2006
- Country
- CRVS United States
- RPAY United States
- Employees
- CRVS N/A
- RPAY N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- RPAY Business Services
- Sector
- CRVS Health Care
- RPAY Consumer Discretionary
- Exchange
- CRVS Nasdaq
- RPAY Nasdaq
- Market Cap
- CRVS 459.0M
- RPAY 469.0M
- IPO Year
- CRVS 2016
- RPAY N/A
- Fundamental
- Price
- CRVS $7.59
- RPAY $5.20
- Analyst Decision
- CRVS Strong Buy
- RPAY Buy
- Analyst Count
- CRVS 4
- RPAY 9
- Target Price
- CRVS $13.75
- RPAY $7.22
- AVG Volume (30 Days)
- CRVS 1.0M
- RPAY 971.3K
- Earning Date
- CRVS 11-04-2025
- RPAY 11-10-2025
- Dividend Yield
- CRVS N/A
- RPAY N/A
- EPS Growth
- CRVS N/A
- RPAY N/A
- EPS
- CRVS N/A
- RPAY N/A
- Revenue
- CRVS N/A
- RPAY $310,367,000.00
- Revenue This Year
- CRVS N/A
- RPAY $0.04
- Revenue Next Year
- CRVS N/A
- RPAY $7.72
- P/E Ratio
- CRVS N/A
- RPAY N/A
- Revenue Growth
- CRVS N/A
- RPAY 1.45
- 52 Week Low
- CRVS $2.54
- RPAY $3.59
- 52 Week High
- CRVS $10.00
- RPAY $9.75
- Technical
- Relative Strength Index (RSI)
- CRVS 58.78
- RPAY 57.37
- Support Level
- CRVS $6.81
- RPAY $4.30
- Resistance Level
- CRVS $7.96
- RPAY $4.75
- Average True Range (ATR)
- CRVS 0.52
- RPAY 0.23
- MACD
- CRVS -0.03
- RPAY 0.07
- Stochastic Oscillator
- CRVS 67.50
- RPAY 94.74
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.